PT-141 Dosage Calculator

Last updated: 2026-11-10

Sources checked: 2026-11-10

📌At a Glance: PT-141 Reconstitution Arithmetic

Commercial Product vs. Research Powder: Bremelanotide is FDA-approved under the brand name Vyleesi as a pre-filled, single-dose auto-injector. Patients using genuine commercial prescriptions never perform reconstitution.
Known-Concentration Mode: If a ready-mixed solution or pharmacy-dispensed vial has an established mg/mL concentration, reconstitution is bypassed; draw volume equals target milligrams divided by concentration.
Common Research Vial Masses: Standard freeze-dried laboratory vials contain 5 mg and 10 mg of active cyclic heptapeptide.
Syringe Calibration: All volumetric conversions assume a standard U-100 insulin syringe (100 units = 1.0 mL, or 0.01 mL per unit graduation mark).

⚖️Regulatory & Compound Status

Verified: 2026-11-10

Bremelanotide is FDA-approved under the proprietary brand name Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The approved commercial formulation is manufactured exclusively as a pre-filled, single-dose auto-injector delivering 1.75 mg of bremelanotide in 0.3 mL of clear aqueous solution (5.83 mg/mL). The commercial product requires no dilution or mixing. Lyophilized powder vials sold online under the chemical designation 'PT-141' are unapproved research chemicals without FDA safety evaluation or good manufacturing practice oversight.

Official Sources:Vyleesi (bremelanotide injection) Prescribing Information,Safety Risks Associated with Certain Bulk Drug Substances Nominated for 503A/503B Compounding

ℹ️What This Tool Cannot Tell You

This calculator cannot provide medical advice, diagnosis, or clinical administration timing.
It cannot provide dosing schedules, frequency protocols, or therapeutic recommendations.
It cannot verify the chemical purity, sterility, or peptide content of unapproved research chemicals.
It cannot guarantee solution stability beyond documented USP <797> multi-dose preservative limits.

This tool converts volumetric liquid measurements and syringe tick marks only. It does not provide medical guidance, dosing schedules, or clinical administration protocols. Review our Medical & Research Disclaimer.

What Is PT-141 Reconstitution Arithmetic?

PT-141 (Bremelanotide, frequently searched as PT 141) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH). Derived as an active metabolite of Melanotan II, PT-141 lacks the C-terminal amide group, selectively binding to central melanocortin receptors (predominantly MC3R and MC4R) in the central nervous system without stimulating cutaneous MC1R-mediated melanogenesis.

While the FDA-approved product (Vyleesi) is supplied exclusively as a factory-assembled auto-injector, laboratory and analytical research facilities acquire PT-141 as a solid, freeze-dried lyophilized cake in glass vials. Reconstitution is the precise chemical dissolution of this dry cake using sterile diluent, primarily bacteriostatic water (sterile water preserved with 0.9% benzyl alcohol). Our pt-141 dosage calculator provides deterministic mathematical conversions across standard research vials and demonstrates known-concentration formulas.

PT-141 Dosage Chart

This reference chart translates intended milligram test masses into volumetric draw units on a standard U-100 syringe across 5 mg and 10 mg research vials. These figures represent illustrative mathematical conversions across standardized benchmark test amounts (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg) and do not represent clinical advice, therapeutic recommendations, or administration protocols.

Vial Size	Bac Water Added	Concentration	Example Amount	Draw Units (U-100)
5 mg	1.0 mL	5.0 mg/mL	0.5 mg	10.0 Units
5 mg	1.0 mL	5.0 mg/mL	1.0 mg	20.0 Units
5 mg	2.0 mL	2.5 mg/mL	0.5 mg	20.0 Units
5 mg	2.0 mL	2.5 mg/mL	1.0 mg	40.0 Units
10 mg	2.0 mL	5.0 mg/mL	0.5 mg	10.0 Units
10 mg	2.0 mL	5.0 mg/mL	1.0 mg	20.0 Units
10 mg	2.0 mL	5.0 mg/mL	1.5 mg	30.0 Units
10 mg	2.0 mL	5.0 mg/mL	2.0 mg	40.0 Units

PT-141 Vial Size and Diluent Conversion Matrix

The table below outlines resulting solution concentrations, unit potencies, and draw units required per 1.0 mg across standard research vials (5 mg and 10 mg) and diluent volumes (1 mL, 2 mL, 3 mL). All values follow the deterministic formula: Concentration (mg/mL) = Vial Mass (mg) ÷ Diluent Volume (mL).

Vial Mass (mg)	Diluent Added (mL)	Concentration (mg/mL)	Potency per Unit (mcg/U)	Units per 1.0 mg Draw
5 mg	1.0 mL	5.00 mg/mL	50.0 mcg/U	20.0 Units
5 mg	2.0 mL	2.50 mg/mL	25.0 mcg/U	40.0 Units
5 mg	3.0 mL	1.67 mg/mL	16.7 mcg/U	60.0 Units
10 mg	1.0 mL	10.00 mg/mL	100.0 mcg/U	10.0 Units
10 mg	2.0 mL	5.00 mg/mL	50.0 mcg/U	20.0 Units
10 mg	3.0 mL	3.33 mg/mL	33.3 mcg/U	30.0 Units

Worked Calculation Example: 10 mg Vial with 2.0 mL Diluent

Example Parameters:

Vial Mass: 10.0 mg solid lyophilized cake
Diluent Added: 2.0 mL sterile Bacteriostatic Water
Target Test Amount: 1.0 mg (1,000 mcg) illustrative calculation
Syringe Standard: U-100 insulin syringe (100 units = 1.0 mL, or 0.01 mL per unit)

Step-by-Step Calculation:

Step 1: Calculate solution concentration = 10.0 mg ÷ 2.0 mL = 5.0 mg/mL (5,000 mcg/mL).
Step 2: Determine volumetric draw = 1.0 mg ÷ 5.0 mg/mL = 0.20 mL.
Step 3: Convert volume to U-100 syringe units = 0.20 mL × 100 units/mL = 20.0 Units.
Step 4: Mathematical Back-Check: 20.0 units × 0.01 mL/unit = 0.20 mL. 0.20 mL × 5.0 mg/mL = 1.0 mg. Result confirms target mass exactly.

Result:

Drawing 20.0 units on a U-100 syringe delivers exactly 1.0 mg of PT-141.

Note: For a 0.5 mg test amount from this same vial: 0.5 mg ÷ 5.0 mg/mL = 0.10 mL = 10.0 units.

Known-Concentration Mode: Reconstitution vs. Pre-Dissolved Label Math

Calculating volume for PT-141 involves two distinct modes depending on the product format:

1. Pre-Filled Commercial Presentation (Known-Concentration Mode):
• The FDA-approved commercial drug Vyleesi is manufactured as a ready-to-use liquid solution in single-dose auto-injectors containing 1.75 mg in 0.3 mL (an active concentration of 5.83 mg/mL).
• If a solution arrives already dissolved with a stated concentration, reconstitution arithmetic is entirely bypassed.
• The draw volume formula simplifies to: Volume (mL) = Target Mass (mg) ÷ Stated Concentration (mg/mL).
• For example, to obtain an illustrative 1.75 mg test amount from a 5.83 mg/mL solution: 1.75 mg ÷ 5.83 mg/mL = 0.30 mL (30 units on a U-100 syringe). Patients with prescription auto-injectors never perform this calculation manually because the device delivers a fixed mechanical dose.

2. Lyophilized Research Vials (Two-Step Reconstitution Mode):
• When starting from a dry powder cake (e.g. 10 mg), the researcher controls the concentration by choosing the diluent volume (e.g. 2.0 mL creates 5.0 mg/mL). Never confuse the total cake mass with the concentration of a pre-mixed liquid.

For a comprehensive guide on decimal conversions, consult our tutorial on how to calculate peptide dosage.

Syringe Unit Resolution and Measurement Precision (per 1.0 mg Target Draw)

This table illustrates what percentage of an illustrative 1.0 mg target draw is contained in a single syringe unit mark on a standard U-100 syringe across various reconstitution setups.

Vial Setup	Concentration	Peptide Mass per Unit	One Unit as % of 1.0 mg Target	Practical Measurement Note
10 mg in 1.0 mL	10.0 mg/mL	100.0 mcg (0.10 mg)	10.0%	Moderate: 1 unit error = 10% deviation
10 mg in 2.0 mL	5.0 mg/mL	50.0 mcg (0.05 mg)	5.0%	Good visual resolution: 20 units = 1.0 mg
5 mg in 2.0 mL	2.5 mg/mL	25.0 mcg (0.025 mg)	2.5%	High visual resolution: 40 units = 1.0 mg
5 mg in 1.0 mL	5.0 mg/mL	50.0 mcg (0.05 mg)	5.0%	Standard concentration: 20 units = 1.0 mg

PT-141 Chemical Characteristics & Laboratory Handling

PT-141 is a synthetic cyclic heptapeptide stabilized by an intramolecular lactam bridge between aspartic acid and lysine residues. This cyclic structure confers greater conformational rigidity and stability than linear peptides, but mechanical shear stress and thermal fluctuations can still cause degradation. When reconstituting, inject bacteriostatic water slowly against the inner glass wall so the liquid flows down gently. Swirl the vial in slow circular motions until completely dissolved into a clear liquid. Do not shake violently.

Store reconstituted solutions upright in continuous refrigeration between 2°C and 8°C (USP <659>). Under FDA multi-dose sterile vial guidance and USP <797> standards, multi-dose vials preserved with 0.9% benzyl alcohol should be discarded within 28 days of first puncture unless product labeling specifies a shorter limit. Never freeze liquid reconstituted peptide solutions. For complete standard operating procedures, consult our guide on how to reconstitute peptides safely.

Common Calculation & Measurement Mistakes

⚠️Attempting to Reconstitute a Pre-Filled Auto-Injector

Commercial bremelanotide (Vyleesi) is pre-dissolved at 5.83 mg/mL in a factory-sealed device. Attempting to add water to pre-filled pens ruins the device mechanism and destroys product sterility.

⚠️Confusing Stated Concentration (mg/mL) with Total Vial Mass (mg)

On liquid vials, the label indicates concentration (e.g. 5 mg/mL). On dry powder vials, the label indicates total mass (e.g. 10 mg). Treating a 10 mg powder vial as a 10 mg/mL liquid before adding diluent leads to extreme volumetric calculation errors.

⚠️Altering Diluent Volume Without Recalculating

Reconstituting a 10 mg vial with 1.0 mL (10 mg/mL) creates a solution twice as concentrated as one prepared with 2.0 mL (5 mg/mL). Drawing the same syringe unit mark delivers twice the active peptide mass.

⚠️Using a U-40 Syringe for U-100 Volume Calculations

U-100 syringes contain 100 units per mL (0.01 mL/unit). U-40 veterinary syringes contain 40 units per mL (0.025 mL/unit). Drawing 20 units on a U-40 syringe delivers 0.50 mL instead of 0.20 mL—causing an unintentional 2.5× volumetric error.

Comparing PT-141 with Laboratory Research Peptides

PT-141 operates on central melanocortin signaling pathways rather than metabolic or growth factor cascades. Understanding its volumetric calculation dynamics compared to other laboratory peptides clarifies preparation techniques:

• Compared to MOTS-c: Both compounds are calculated in milligram quantities. However, MOTS-c research vials often range up to 20 mg or 40 mg, requiring larger diluent volumes to preserve measurement precision.
• Compared to KPV Peptide: KPV is also derived from alpha-MSH (representing the C-terminal tripeptide residues 11–13). However, KPV is calculated in microgram increments (250 mcg to 500 mcg) for peripheral anti-inflammatory evaluation, whereas PT-141 is calculated in milligram increments.
• Universal Calculation Standards: Regardless of peptide structure, all dry powder reconstitution follows the fixed physical relationship between dry mass, liquid diluent volume, and syringe graduation scale.

Reconstitution Protocol Summary

Lyophilized PT-141 cake dissolves cleanly when sterile diluent is introduced gently under aseptic conditions.

Syringe Reading Diagram

U-100 Syringe Graduation & Measurement Line (PT-141)

Standard Reconstitution Protocol

Review our standardized 5-step sterile reconstitution guide for full vial preparation, alcohol disinfection, and needle handling SOPs.

Universal Step-by-Step Reconstitution Guide→

❄️ Storage & Shelf-Life Notice (PT-141)

Store reconstituted PT-141 solutions refrigerated at 2°C–8°C (36°F–46°F). Protect from prolonged ultraviolet light exposure. Never freeze reconstituted liquid solutions.

⚠️ Common Preparation Mistakes to Avoid

Common errors include attempting to dilute pre-filled commercial auto-injectors, confusing stated concentration with total vial fill, and using U-40 syringes.

PT-141 Dosing FAQ

Does the FDA-approved bremelanotide product require reconstitution?↓

No. The approved commercial drug (Vyleesi) is supplied as a pre-filled, single-dose auto-injector containing pre-dissolved solution (1.75 mg in 0.3 mL). It does not require water addition or mixing. Reconstitution math applies exclusively to solid lyophilized powder vials.

How do I calculate draw volume from a printed mg/mL concentration?↓

Divide your target milligram amount by the concentration printed on the vial: Volume (mL) = Target Mass (mg) ÷ Concentration (mg/mL). Then multiply by 100 to find your U-100 syringe units. For example, 1.0 mg divided by 5.0 mg/mL equals 0.20 mL (20 units).

Why can two vial labels show different mg/mL concentrations for the same peptide?↓

Because concentration is not an intrinsic chemical property of the peptide; it depends entirely on the proportion of active compound dissolved in a given volume of diluent. A 10 mg vial dissolved in 1.0 mL is 10 mg/mL, whereas that same 10 mg vial dissolved in 2.0 mL is 5 mg/mL.

What syringe standard should be used for measuring PT-141 draw volumes?↓

All calculations on this page are calibrated for standard U-100 insulin syringes (100 units = 1.0 mL, or 0.01 mL per unit). For draws of 20 to 40 units (0.20 mL to 0.40 mL), a 0.3 mL or 0.5 mL U-100 syringe provides the highest graduation readability.

Can reconstituted PT-141 liquid be stored in the freezer?↓

No. Liquid reconstituted peptide solutions must never be frozen. Ice crystal lattice formation causes mechanical shear stress that can denature cyclic peptide bonds. Store reconstituted liquid refrigerated at 2°C–8°C.

Related Peptide Calculators & Stacks

KPV

Calculate reconstitution volume, solution concentration, and U-100 syringe units for research KPV vials.

Calculate KPV→

MOTS-c

Calculate reconstitution volume, solution concentration, and U-100 syringe units for research MOTS-c vials.

Calculate MOTS-c→

Related Reconstitution & Dosing Guides

View All FAQs→

MOTS-c FAQ

How to Reconstitute MOTS-c?

→

General Peptide FAQ

How to Reconstitute Peptides?

→